|Bid||33.13 x 1000|
|Ask||33.28 x 1000|
|Day's Range||33.12 - 33.23|
|52 Week Range||17.61 - 35.40|
|PE Ratio (TTM)||22.66|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Learn more about Valeant Pharmaceuticals International Inc. and three of the top companies that Valeant owns or operates as subsidiaries.
Insurers report strong Q1 results despite Obamacare losses; Fresenius plants an Akorn; and Express Scripts' battle with Anthem gets real.
A $4.3 billion acquisition provides additional growth opportunity for this European healthcare giant.